Background: Since Hepatitis-B patients coinfected/ superinfected with Hepatitis-D virus are increasing in South-East Asian countries like Pakistan and India, so the study was designed to observe the effects of antiviral drugs like lamivudine on sero-conversion of HBeAg positive cases. Methods: This study was conducted at Hepatology clinic, Lahore Pakistan, over a period of 2 years from 2007 to 2009. A total of 97 ELISA confirmed Hepatitis-B positive patients with deranged liver functions for 6 months were recruited. All were screened for HBeAg, HBV-DNA and anti-HDV using ELISA test. They were subdivided in 2 groups. GroupA included patients who were HBeAg and HBV-DNA positive but Anti-HDV negative, while group B comprised of patients positive for HBeAg, HBV-DNA and Anti-HDV (all positive). Reverse transcriptase inhibitor (RTI), lamivudine in a dose of 100mg/day was given to all till sero-conversion. Results: Out of total 97 patients 64% (n = 62) were males, mean age 56±4 years. 55 cases were in group A and 42 were in group B. At the beginning of study, mean HBeAg was 284±179 in group A and 137±151 in group B. Within a period of 6 months, ALT became normal in 70% patients (n = 38) among group A, and 19% (n = 8) among group B. Serum viral markers did not change much till 1 year of treatment and was significantly slower among group B. 34% (n = 19) patients in group A and 12% (n = 5) patients in group B sero-converted completely at the end of 2 years therapy. Conclusions: Hepatitis-B patients co-infected with Hepatitis-D virus have a chance of seroconversion and still the effective therapy options are available to treat such scenario. Effort should be maximized to catch the diagnosis earlier and start the therapy in an optimal mode so as to get enhanced benefits of antiviral drugs like lamivudine. 
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